

## SUPPLEMENTARY MATERIAL

### Supplementary methods

Sanger sequencing and resistance reporting was undertaken by University College London Hospitals clinical diagnostic virology laboratory. Illumina HBV whole genome sequencing was performed in Oxford with a previously described protocol [9], with the addition of micrococcal nuclease for host nucleic acid depletion and sequencing on Illumina Miseq v3 with 2x300bp paired end reads. Bioinformatic workflow as described previously [9].

### Supplementary Table 1: HBV drug resistance report from a clinical diagnostic virology laboratory, based on a serum sample submitted during rebound (year 25).

Polymorphisms in HBV reverse transcriptase (RT) codons 91-285 are listed, and summary of the interpretation of the resistance profile as reported by clinical diagnostic virology laboratory (based on <https://hbv.geno2pheno.org/>).

Genotype	Polymorphisms in RT domain	Clinical interpretation of resistance associated mutations
Dual infection with genotypes A and G	I53IS, T54A, I103V, N118D, I121S, N122H/I/L, N123D, N124H, M129L, W153R, V163I, A181T, V207I/M, L217R, I253V, V266A/I/T	<ul style="list-style-type: none"> <li>• Lamivudine – resistant (181T)</li> <li>• Telbivudine - resistant (181T)</li> <li>• Adefovir – resistant (181T)</li> <li>• Entecavir – susceptible</li> <li>• Tenofovir - susceptible</li> </ul>

**Supplementary Table 2: Resistance associated mutations (RAMs) listed in EASL guidance [7], Genotype A/G consensus and polymorphisms identified in HBV isolated from this individual.**

RAM	Reference sequence (NB. same aa for Geno A/G at all given sites)	Patient HBV sequence (UCLH report)	Patient HBV sequence (Illumina data)		Clinical interpretation from EASL guidance (if detected)			
			Consensus	Minority variant	LAM	ETV	ADV	TDF/TAF*
I169T (in combination)	I		I (100%)					
V173L (in combination)	V		V (99%)	G (1%)				
L180M	L		L (100%)					
A181T/V	A	A, T	A (97%)	T (3%)	I	S	R	I
T184G (in combination)	T		T (100%)					
S202I/G (in combination)	S		S (100%)					
M204V/I	M		M (100%)					
N236T	N		N (100%)					
M250V (in combination)	M		M (100%)					

The amino acid substitution profiles are shown in the left column and the level of susceptibility is given for each drug:

S (sensitive), I (intermediate/reduced susceptibility), R (resistant).

ETV, entecavir; TDF tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; LAM, lamivudine; ADV, adefovir

\*In vitro data for tenofovir, in vivo data for TDF, no clinical data for TAF.